Recipient and transplantation characteristics according to preparative regimen (N = 932 donor/recipient pairs undergoing harvest/transplantation)
| Variable . | Myeloablative . | Reduced intensity . | Nonmyeloablative . | P . |
|---|---|---|---|---|
| Recipient characteristics | ||||
| No. of patients | 611 | 160 | 161 | |
| No. of centers | 79 | 52 | 36 | |
| Median follow-up time among survivors, d (range) | 1224 (228-2612) | 1123 (364-2200) | 1417 (593-2295) | |
| Male recipients, n (%) | 345 (56) | 92 (58) | 90 (56) | .957 |
| Recipient race/ethnicity | .011* | |||
| White, n (%) | 525 (86) | 142 (89) | 153 (95) | |
| Hispanic, n (%) | 39 (6) | 6 (4) | 4 (2) | |
| Asian/Pacific Islander, n (%) | 19 (3) | 6 (4) | 1 (<1) | |
| Black/African American, n (%) | 18 (3) | 5 (3) | 2 (1) | |
| Other/declines, n (%) | 10 (2) | 1 (<1) | 1 (< 1) | |
| Recipient age, median (range) | 38 (<1 to 65) | 56 (1-75) | 57 (17-73) | < .001 |
| 0-9 y, n (%) | 28 (5) | 2 (1) | 0 (0) | < .001 |
| 10-19 y, n (%) | 60 (10) | 6 (4) | 2 (1) | |
| 20-29 y, n (%) | 110 (18) | 7 (4) | 8 (5) | |
| 30-39 y, n (%) | 122 (20) | 17 (11) | 6 (4) | |
| 40-49 y, n (%) | 174 (28) | 19 (12) | 22 (14) | |
| 50-59 y, n (%) | 105 (17) | 66 (41) | 67 (42) | |
| 60 y or older, n (%) | 12 (2) | 43 (27) | 56 (35) | |
| Karnofsky performance score | .258 | |||
| 90-100, n (%) | 371 (61) | 91 (57) | 87 (54) | |
| 10-80, n (%) | 184 (30) | 54 (34) | 63 (39) | |
| Unknown, n (%) | 56 (9) | 15 (9) | 11 (7) | |
| Disease and stage | < .001† | |||
| Acute myelogenous leukemia, n (%) | 249 (41) | 99 (62) | 71 (44) | |
| First CR, n (%) | 87 (14) | 33 (21) | 34 (21) | |
| Second CR, n (%) | 56 (9) | 21 (13) | 17 (11) | |
| Third CR, n (%) | 4 (1) | 2 (1) | 2 (1) | |
| Not in remission, n (%) | 102 (17) | 43 (27) | 18 (11) | |
| Acute lymphoblastic leukemia, n (%) | 159 (26) | 10 (6) | 16 (10) | |
| First CR, n (%) | 49 (8) | 4 (3) | 9 (6) | |
| Second CR, n (%) | 46 (8) | 3 (2) | 4 (2) | |
| Third CR, n (%) | 21 (3) | 1 (< 1) | 1 (< 1) | |
| Not in remission, n (%) | 43 (7) | 2 (1) | 2 (1) | |
| Chronic myelogenous leukemia, n (%) | 95 (16) | 15 (9) | 24 (15) | |
| First CP, n (%) | 40 (7) | 7 (4) | 13 (8) | |
| Accelerated phase/second CP, n (%) | 44 (7) | 5 (3) | 10 (6) | |
| Blast phase, n (%) | 11 (2) | 3 (2) | 1 (< 1) | |
| Myelodysplastic syndromes (MDS), n (%) | 108 (18) | 36 (23) | 50 (31) | |
| Refractory anemia, n (%) | 31 (5) | 9 (6) | 6 (4) | |
| RAEB/RAEB-T, n (%) | 35 (6) | 14 (9) | 13 (8) | |
| Other MDS, n (%) | 42 (7) | 13 (8) | 31 (19) | |
| Disease risk | .013 | |||
| Early, n (%) | 207 (34) | 53 (33) | 62 (39) | |
| Intermediate, n (%) | 213 (35) | 45 (28) | 65 (40) | |
| Advanced, n (%) | 191 (31) | 62 (39) | 34 (21) | |
| Transplantation characteristics | ||||
| HLA match | .021 | |||
| Well-matched, n (%) | 359 (59) | 88 (55) | 108 (67) | |
| Partially matched, n (%) | 173 (28) | 53 (33) | 46 (29) | |
| Mismatched, n (%) | 79 (13) | 19 (12) | 7 (4) | |
| Donor/recipient sex match | .295 | |||
| Male/male, n (%) | 212 (35) | 65 (41) | 52 (32) | |
| Male/female, n (%) | 143 (23) | 42 (26) | 46 (29) | |
| Female/male, n (%) | 133 (22) | 27 (17) | 38 (24) | |
| Female/female, n (%) | 123 (20) | 26 (16) | 25 (16) | |
| Donor/recipient CMV status | .200 | |||
| Negative/negative, n (%) | 187 (31) | 35 (22) | 52 (33) | |
| Negative/positive, n (%) | 199 (33) | 63 (39) | 57 (36) | |
| Positive/negative, n (%) | 88 (15) | 20 (13) | 21 (13) | |
| Positive/positive, n (%) | 131 (22) | 42 (26) | 29 (18) | |
| Unknown, n (%) | 6 (N/A) | 0 (N/A) | 2 (N/A) | |
| TBI, n (%) | 399 (65) | 25 (16) | 129 (80) | < .001 |
| GVHD prophylaxis | < .001‡ | |||
| CsA + MTX ± other, n (%) | 327 (54) | 25 (16) | 4 (2) | |
| CsA ± other (no MTX), n (%) | 18 (3) | 55 (34) | 132 (82) | |
| FK506 + MTX ± other, n (%) | 220 (36) | 33 (21) | 12 (7) | |
| FK506 ± other (no MTX), n (%) | 40 (7) | 46 (29) | 8 (5) | |
| Other, n (%)§ | 6 (<1) | 1 (<1) | 5 (3) | |
| Use of planned growth factors, n (%) | 187 (31) | 66 (41) | 27 (17) | < .001 |
| Variable . | Myeloablative . | Reduced intensity . | Nonmyeloablative . | P . |
|---|---|---|---|---|
| Recipient characteristics | ||||
| No. of patients | 611 | 160 | 161 | |
| No. of centers | 79 | 52 | 36 | |
| Median follow-up time among survivors, d (range) | 1224 (228-2612) | 1123 (364-2200) | 1417 (593-2295) | |
| Male recipients, n (%) | 345 (56) | 92 (58) | 90 (56) | .957 |
| Recipient race/ethnicity | .011* | |||
| White, n (%) | 525 (86) | 142 (89) | 153 (95) | |
| Hispanic, n (%) | 39 (6) | 6 (4) | 4 (2) | |
| Asian/Pacific Islander, n (%) | 19 (3) | 6 (4) | 1 (<1) | |
| Black/African American, n (%) | 18 (3) | 5 (3) | 2 (1) | |
| Other/declines, n (%) | 10 (2) | 1 (<1) | 1 (< 1) | |
| Recipient age, median (range) | 38 (<1 to 65) | 56 (1-75) | 57 (17-73) | < .001 |
| 0-9 y, n (%) | 28 (5) | 2 (1) | 0 (0) | < .001 |
| 10-19 y, n (%) | 60 (10) | 6 (4) | 2 (1) | |
| 20-29 y, n (%) | 110 (18) | 7 (4) | 8 (5) | |
| 30-39 y, n (%) | 122 (20) | 17 (11) | 6 (4) | |
| 40-49 y, n (%) | 174 (28) | 19 (12) | 22 (14) | |
| 50-59 y, n (%) | 105 (17) | 66 (41) | 67 (42) | |
| 60 y or older, n (%) | 12 (2) | 43 (27) | 56 (35) | |
| Karnofsky performance score | .258 | |||
| 90-100, n (%) | 371 (61) | 91 (57) | 87 (54) | |
| 10-80, n (%) | 184 (30) | 54 (34) | 63 (39) | |
| Unknown, n (%) | 56 (9) | 15 (9) | 11 (7) | |
| Disease and stage | < .001† | |||
| Acute myelogenous leukemia, n (%) | 249 (41) | 99 (62) | 71 (44) | |
| First CR, n (%) | 87 (14) | 33 (21) | 34 (21) | |
| Second CR, n (%) | 56 (9) | 21 (13) | 17 (11) | |
| Third CR, n (%) | 4 (1) | 2 (1) | 2 (1) | |
| Not in remission, n (%) | 102 (17) | 43 (27) | 18 (11) | |
| Acute lymphoblastic leukemia, n (%) | 159 (26) | 10 (6) | 16 (10) | |
| First CR, n (%) | 49 (8) | 4 (3) | 9 (6) | |
| Second CR, n (%) | 46 (8) | 3 (2) | 4 (2) | |
| Third CR, n (%) | 21 (3) | 1 (< 1) | 1 (< 1) | |
| Not in remission, n (%) | 43 (7) | 2 (1) | 2 (1) | |
| Chronic myelogenous leukemia, n (%) | 95 (16) | 15 (9) | 24 (15) | |
| First CP, n (%) | 40 (7) | 7 (4) | 13 (8) | |
| Accelerated phase/second CP, n (%) | 44 (7) | 5 (3) | 10 (6) | |
| Blast phase, n (%) | 11 (2) | 3 (2) | 1 (< 1) | |
| Myelodysplastic syndromes (MDS), n (%) | 108 (18) | 36 (23) | 50 (31) | |
| Refractory anemia, n (%) | 31 (5) | 9 (6) | 6 (4) | |
| RAEB/RAEB-T, n (%) | 35 (6) | 14 (9) | 13 (8) | |
| Other MDS, n (%) | 42 (7) | 13 (8) | 31 (19) | |
| Disease risk | .013 | |||
| Early, n (%) | 207 (34) | 53 (33) | 62 (39) | |
| Intermediate, n (%) | 213 (35) | 45 (28) | 65 (40) | |
| Advanced, n (%) | 191 (31) | 62 (39) | 34 (21) | |
| Transplantation characteristics | ||||
| HLA match | .021 | |||
| Well-matched, n (%) | 359 (59) | 88 (55) | 108 (67) | |
| Partially matched, n (%) | 173 (28) | 53 (33) | 46 (29) | |
| Mismatched, n (%) | 79 (13) | 19 (12) | 7 (4) | |
| Donor/recipient sex match | .295 | |||
| Male/male, n (%) | 212 (35) | 65 (41) | 52 (32) | |
| Male/female, n (%) | 143 (23) | 42 (26) | 46 (29) | |
| Female/male, n (%) | 133 (22) | 27 (17) | 38 (24) | |
| Female/female, n (%) | 123 (20) | 26 (16) | 25 (16) | |
| Donor/recipient CMV status | .200 | |||
| Negative/negative, n (%) | 187 (31) | 35 (22) | 52 (33) | |
| Negative/positive, n (%) | 199 (33) | 63 (39) | 57 (36) | |
| Positive/negative, n (%) | 88 (15) | 20 (13) | 21 (13) | |
| Positive/positive, n (%) | 131 (22) | 42 (26) | 29 (18) | |
| Unknown, n (%) | 6 (N/A) | 0 (N/A) | 2 (N/A) | |
| TBI, n (%) | 399 (65) | 25 (16) | 129 (80) | < .001 |
| GVHD prophylaxis | < .001‡ | |||
| CsA + MTX ± other, n (%) | 327 (54) | 25 (16) | 4 (2) | |
| CsA ± other (no MTX), n (%) | 18 (3) | 55 (34) | 132 (82) | |
| FK506 + MTX ± other, n (%) | 220 (36) | 33 (21) | 12 (7) | |
| FK506 ± other (no MTX), n (%) | 40 (7) | 46 (29) | 8 (5) | |
| Other, n (%)§ | 6 (<1) | 1 (<1) | 5 (3) | |
| Use of planned growth factors, n (%) | 187 (31) | 66 (41) | 27 (17) | < .001 |
CR indicates complete remission; CP, chronic phase; RAEB, refractory anemia with excess of blasts; RAEB-T, RAEB in transformation; N/A, not applicable; and MTX, methotrexate.
White compared with others.
Comparing broad diseases.
CsA compared with FK506.
Other GVHD prophylaxis included MTX, mycophenolate mofetil, corticosteroids, and G-CSF.